Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial

Claire Harrison, Ruben A. Mesa, Moshe Talpaz, Haifa Kathrin Al‐Ali, Blanca Xicoy, Francesco Passamonti, Francesca Palandri, Giulia Benevolo, Alessandro M. Vannucchi, Clémence Mediavilla, Alessandra Iurlo, Inho Kim, Shelonitda Rose, Patrick A. Brown, Christopher Hernandez, Jia Wang, Jean‐Jacques Kiladjian